United States: Product Liability Law & Strategy: Challenges To The Admissibility Of Evidence In The ‘Omics' Era

Genetic technologies have been a presence in United States courtrooms for decades. In 1987, Tommie Lee Andrews became the first person in the United States to be convicted of a crime based on DNA evidence, spurring the first appellate decision on the admissibility of the results of a genetic test. Andrews v. State, 533 So.2d 841 (Fla. Dist. Ct. App. 1988). Two years later, the case of State v. Woodall, 385 S.E.2d 253 (W. Va. 1989), brought the issue of DNA evidence to a state's highest court, which concluded that the reliability of genetic testing was generally accepted in the scientific community.

A review of these cases and their progeny demonstrate that genetics in the courtroom has historically been focused on the "who" and "what" —seeking to resolve paternity, to include or exclude individuals as criminals or victims of crimes, or to identify the mode and manner of criminal activity. However, due to our increased understanding of human genetics, there has been a shift in, and expansion of, the use of genetics in the courtroom to address the "how" and "why" —the causation of, or susceptibility to —disease in mass tort and products liability litigations.

Even though the technology is cutting edge, the admissibility of expert testimony regarding genetic testing is subject to age-old rules. This article reviews some recent decisions regarding genomics, and provides practice pointers for litigators involved in these types of proceedings.

Embrace the 'Omics' Era

Genomics is the study of genomes — the complete set of DNA within a cell of an organism. Genomics, family history and the environment each play a significant role in the etiology of disease.

The Human Genome Project was an international scientific research project formally launched in 1990 and declared complete in 2003, culminating in the sequencing of approximately 92% of the human genome, the blueprint of human life. Today, thousands of human genomes have been sequenced, and many more mapped to lower levels of resolution. The widely held expectation has been that genomic studies will lead to a greater understanding of gene structure and function, resulting in advances in the diagnosis and treatment of disease, individualized medicine, and advances in fields such as biology and evolution. However, genomic studies have also birthed a sideline of implications in the courtroom as well.

Pharmacogenomics, a relatively new field of study, explores how a person's genome affects response to drugs. While medications have historically been engineered using a "one-size-fits-all" approach, a person's genetic make-up affects the way drugs are metabolized, and the anticipated side effects. Toxicogenomics explores the genome's response to adverse environmental exposures. As with the response to medications, each person is unique in his or her susceptibility to toxic agents, and a person's genome may divulge information regarding: 1) an individual's susceptibility to toxin exposure; and 2) whether or not an adverse health effect was in fact caused by an exposure to a toxin in the environment.

Given the foregoing, it should come as little surprise that genetics and genomics are being used as both a sword by plaintiffs, and in certain circumstances as a shield by defendant manufacturers, to prove or disprove the cause of disease in toxic tort and product liability litigations. In Bowen v. E.I Du Pont de Nemours & Co., 2005 WL 1952859 (Del. Sup. Ct. June 23, 2005), for example, genetic testing demanded by defendants, and performed mid-lawsuit, demonstrated that a child's arrested in-utero development was caused not by maternal exposure to the defendant's fungicide, as alleged by the plaintiff, but instead by a "CHD7″ gene mutation, sounding a death knell for that plaintiff's case.

In other instances, genetic pre-dispositions or susceptibilities are being used to argue "eggshell plaintiff" claims — that a tortfeasor aggravated preexisting physical or mental conditions. In VanSlembrouck v. Halperin, 2014 WL 5462596 (Mich. Ct. App. 2014), for example, the plaintiff parents of a child with a rare genetic disease successfully presented expert evidence that birth trauma caused by improper care markedly worsened and exacerbated deficits attributable to the child's genetic condition. Genetic pre-dispositions or susceptibilities may also form the basis of duty-to-warn claims or claims for medical monitoring.

In the Courtroom: Top Tips

It is widely recognized that disease conditions often have multiple etiologies, and there is usually no direct evidence of which possible cause produced a disease in a particular individual. Genetic methods and data have the potential to fill certain of these scientific gaps, and are gaining increasing use in the courtroom. Simply stated, the "omics" era is here to stay, and practitioners need to obtain a working knowledge of the use of genomics in litigation.

1. Don't speculate —While it is recognized that genetics plays a role in disease etiology, general arguments without reasoned scientific support will not be admissible in litigation.

Genetic methods and data have started to fill gaps in connection with disease etiology, but courts will not hesitate to exclude evidence and arguments not supported by reasonable and tested scientific data. The standard for admissibility of scientific evidence remains the same, and is not applied differently simply because the arguments in issue relate to genetics having a role in disease etiology.

In 1923, the Circuit Court for the District of Columbia set forth the Frye standard for evaluating expert evidence. Frye v. United States, 293 F. 1013 (D.C. Cir. 1923). Under its teaching, trial courts, when faced with a challenge to the admissibility of expert testimony, admit the testimony if the methods the expert used are generally accepted as reliable in the scientific community. In 1993, the United States Supreme Court, in Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993), held that the Federal Rules of Evidence superseded Frye as the standard for admissibility of expert evidence in federal courts.

Under Federal Rule 702 (the Daubertstandard), consideration is given to whether the theory or technique the expert employs is generally accepted, whether the theory has been subjected to peer review and publication, whether the theory can and has been tested, whether the known or potential rate of error is acceptable, and whether there are standards controlling the technique's operation. Daubert is the standard employed by federal courts and the majority of state courts; however, there are state jurisdictions that still follow the Frye framework.

In In re E.I. du Pont de Nemours and Co. C-8 Personal Injury Litigation, 2017 WL 237778 (S.D. Ohio Jan. 11, 2017), the court refused to credit an attack on the reliability of the plaintiff's expert testimony. According to the defendant, the plaintiff's expert had not properly considered a genetic linkage and family history between testicular and ovarian malignancies when offering evidence of disease causation. As the court explained in part, the scientific evidence alluded to by the defense was merely "emerging" and "evolving," and was not yet accepted in the relevant scientific community. General arguments unsupported by accepted science could play no role in the litigation.

Likewise, in pharmacogenomics litigations, plaintiffs have been largely unsuccessful in advancing arguments of genetic predisposition to drug reaction without concrete scientific data. See, e.g., Mills v. Bristol-Myers Squibb Co., 2011 WL 4708850 (D. Ariz. Oct. 7, 2011) (dismissing claims at motion to dismiss stage that plaintiff may suffer genetic predisposition affecting drug reaction because plaintiff did not allege scientific facts upon which to conclude she carried genetic variant in issue).

2. Ensure that expert witnesses consider genetic data related to disease.

While mere speculation will not pass muster, expert witnesses in this day and age must consider and grapple with genetic data that does exist, or they may find their expert analysis excluded as unreliable.

In addition to general admissibility standards, two causation principles apply in the context of medical causation: A plaintiff must establish both general (whether a substance is capable of causing a particular injury) and specific (whether a substance in fact caused the injury in issue) causation. General causation is often proven through methodologies drawn from epidemiology and toxicology, and include the dose-response relationship, epidemiological studies, background risk of disease, an understanding of the physiological mechanisms involved, and clinical studies or tests. Specific causation is frequently demonstrated via differential diagnosis, a technique of identifying the cause of a medical problem by eliminating the likely causes until the most probable one is isolated.

With regard to differential diagnosis, courts have increasingly required expert witnesses to consider genetic data relating to disease. In Henricksen v. ConocoPhillips Co., 605 F. Supp. 2d 1142 (E.D. Wash. 2009), for example, the court excluded the specific causation opinion of the plaintiff's medical expert as unreliable. In this benzene exposure litigation, the plaintiff's expert had opined that the plaintiff suffered leukemia instigated by occupational exposure to benzene in gasoline. The court found the opinion to be unreliable because the expert did not consider distinct patterns of chromosomal aberrations that the scientific literature demonstrates accompany benzene exposure-induced leukemia, as opposed to idiopathic leukemia; therefore, the differential diagnosis performed by the expert was incomplete.

3. Make a reasoned decision as to whether to genetically test (for plaintiff's counsel) or to demand genetic testing (for defendant's counsel).

Finally, while courts increasingly require expert witnesses to consider genetic data, this does not necessarily translate into a requirement for genetic testing in all instances. In considering whether to conduct or demand genetic testing, an attorney must evaluate the impact of a negative or positive result, and must also consider the jurisdiction's rules for admissibility, as well as a plaintiff's clinical presentation, family history, and the opinions of consulting experts and treating physicians.

In N.K. v. Abbott Labs, 2017 WL 2241507 (E.D.N.Y. May 22, 2017), the court found a plaintiff's expert testimony inadmissible because the expert failed to reliably opine on specific causation via differential diagnosis given that there had been no genetic testing, and the expert could not rule out a genetic cause for the plaintiff's condition. In that matter, no less than four medical providers recommended genetic testing given the child's clinical presentation of disease.

The defendants in Kiker v. Smithkline Beecham Corp. argued for the same result —€ the exclusion of the plaintiff's expert testimony, in part for failure to conduct genetic tests. 2016 WL 7974206 (S.D. Ohio Apr. 25, 2016) (trial motion). However, unlike in the N.K. matter, the patient in Kiker did not present with clinical signs that suggested a genetic cause for his cardiac malformation, and the child's treating physician had determined that genetic testing was not needed. Kiker v. Smithkline Beecham Corp., 2016 WL 7974211 (S.D. Ohio Nov. 18, 2016) (trial motion). Under these facts, and notwithstanding the expert's failure to conduct genetic tests, the court in Kiker found the expert's testimony admissible under Daubert and the Federal Rules. 2016 WL 8189286 (S.D. Ohio Dec. 15, 2016).

Conclusion

There can be no doubt that genetic methods and data have the potential to fill gaps in our understanding of disease etiology, and that this knowledge will continue to become forefront in the courtroom in toxic tort and certain product liability litigations. Litigators in these fields need to become conversant with the technology while also recognizing that our understanding of the human genome is still markedly incomplete, rendering each case, and the admissibility of expert testimony in each litigation, extremely nuanced and fact-specific.

This article was published in the September 2017 edition of Law Journal Newsletter's Product Liability Law & Strategy.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions